Meeting
2013 ASCO Annual Meeting
Clinical guideline on the prophylactic use of g-CSF on neutropenia by chemotherapy.
Authors
Roberto Rivera-Luna
Instituto Nacional de Pediatria, Mexico City, Mexico
Roberto Rivera-Luna , Alejandro G Gonzalez-Garay , Liliana Velasco-Hidalgo , Jose Luis Mayorga-Butron
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics - Immunotherapy
Track
Developmental Therapeutics
Sub Track
Immunotherapy and Biologic Therapy
Citation
J Clin Oncol 31, 2013 (suppl; abstr 3050)
DOI
10.1200/jco.2013.31.15_suppl.3050
Abstract #
3050
Poster Bd #
15A
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Genitourinary Cancers Symposium
A retrospective review of primary prophylaxis with granulocyte-colony stimulating factor (G-CSF) for patients with genitourinary malignancies receiving chemotherapy during the COVID-19 pandemic and implications for the future.
First Author: Nely Mercy Diaz Mejia
Poster
2022 ASCO Quality Care Symposium
An exploratory comparative effectiveness analysis of febrile neutropenia incidence among patients with cancer receiving granulocyte colony stimulating factors.
First Author: Pamala A. Pawloski
Poster
2022 ASCO Annual Meeting
Real-world effectiveness of prophylactic granulocyte colony-stimulating factor (G-CSF) early (week 1) and late (weeks 2-3) in the cycle for the prevention of febrile neutropenia (FN) among patients (pts) with breast cancer (BC) after high FN–risk chemotherapy (chemo).
First Author: Douglas W. Blayney
Poster
2021 ASCO Quality Care Symposium
Association of primary prophylactic (PP) granulocyte-colony stimulating factor (G-CSF) use with chemotherapy dose modifications and relative dose intensity (RDI) among breast cancer patients receiving high-risk regimens for febrile neutropenia (FN).
First Author: Jaime Shaw